Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781306 | 1.00 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL27712904 | 1.00 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL1023071 | 1.00 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL7570219 | 0.98 | ACHE (0.61) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL5696599 | 0.94 | EPHX1 (0.70) | ACHEEPHX1 | |
| SCHEMBL1857424 | 0.94 | EPHX1 (0.70) | ACHEEPHX1 | |
| SCHEMBL1836300 | 0.94 | ACHE (0.55) | ACHEEPHX1HDAC3HDAC4HDAC1 | |
| SCHEMBL4647121 | 0.94 | EPHX1 (0.70) | ACHEEPHX1 | |
| SCHEMBL2987477 | 0.94 | EPHX1 (0.70) | ACHEEPHX1 | |
| SCHEMBL2987259 | 0.94 | EPHX1 (0.70) | ACHEEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140883-A1 | NOVEL MEMBRANES AND PREPARATION THEREOF | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-05-11 | — | — | US | disclosed |
| US-9446139-B2 | Polymer-based compositions and conjugates of HIV entry inhibitors | NEKTAR THERAPEUTICS (US) | 2016-09-20 | — | — | US | disclosed |
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171162-A1 | POLYMER CONJUGATES OF THYMOSIN ALPHA 1 PEPTIDES | TMSB4X, TMSB10, TAP1 | ACHE 3516/4885EPHX1 1086/4885HDAC3 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.